Inclusion Criteria:  Participant scheduled for elective distal pancreatectomy or radical antegrade modular pancreatosplenectomy (RAMPS), via open or laparoscopic technique Participant >= 18 years of age Ability to understand nature and individual consequences of clinical trial Written informed consent from participant or legally authorized representative For participants of childbearing potential, a negative pregnancy test and adequate contraception until 14 days after trial intervention  Exclusion Criteria:  Known hypersensitivity to any BTX preparation or to any of the components in the formulation Infection at the proposed injection site, including cholangitis Anatomy incompatible with planned intervention (e.g., Roux-en-Y gastric bypass, distal gastrectomy with Roux-en-Y or Billroth II reconstruction) Acute pancreatitis within 2 weeks of planned study intervention American Society of Anesthesiologists (ASA) score > III Serious cardiovascular disease (e.g., myocardial infarction in the past year, New York Heart Association [NYHA] III/IV congestive heart failure, unstable angina) Creatinine clearance < 30 mL/min Liver cirrhosis (of any Child-Pugh grade) Neuromuscular or any neurological disease with associated increased risk for a participant undergoing BTX injection Prior BTX administration with either positive or absent testing for neutralizing antibodies to BTX Inability to obtain informed consent due to comprehension or language barrier Inability to comply with study and/or follow-up procedures Pregnancy or lactation Any condition that could result in undue risk for the participant and/or influence outcome measures (in the opinion of the investigator)